“Research use only” peptides are vials sold with a label saying the contents are not for human use, often while the same seller promotes them for weight loss, healing or muscle. The FDA has said these products are “falsely labeled,” and that a disclaimer does not make human use legal. The label also tells you something practical: nobody is claiming the product was made, tested or released as a medicine.
This guide explains where the phrase comes from, how US law judges what a product is for, and what testing of these products has found.
Where the “research use only” label comes from
The wording is borrowed from rules for laboratory diagnostic products. Under FDA labeling rules for in vitro diagnostics, a product still in the laboratory research phase must carry the statement “For Research Use Only. Not for use in diagnostic procedures.” That provision covers test kits and reagents used on specimens in a lab. It was not written for injectable substances sold to the public.
Genuine human research with an unapproved drug uses a different label. Under the investigational new drug rules, the package must say “Caution: New Drug—Limited by Federal (or United States) law to investigational use,” and the labeling must not represent the drug as safe or effective for what is being studied. That is the label for drugs supplied to clinical investigations under FDA rules. A research use only vial bought online is not part of that system.
Why the label does not decide what the product is
US law looks at what a product is meant to do, not only at what its label says. A drug includes any article intended to treat or prevent disease, or intended to affect the structure or any function of the body. FDA regulations say intended use is the seller’s “objective intent,” which may be shown by “labeling claims, advertising matter, or oral or written statements” and by the circumstances in which the article is distributed.
So a research use only peptide sold alongside before-and-after photos, “protocols” or injection guides can still be treated as a drug. If it is an unapproved drug, selling it for human use is unlawful. See Are peptides legal? for the wider picture, including the 2026 changes to the FDA’s compounding categories.
What the FDA has said about these products
On its page on unapproved GLP-1 drugs (current as of October 1, 2026), the FDA says it has warned companies that sold semaglutide, tirzepatide, retatrutide, survodutide or mazdutide “falsely labeled ‘for research purposes’ or ‘not for human consumption.'” It says these products “have been sold directly to consumers for human use with dosing instructions.” It urges consumers not to buy them because they are “of unknown quality and may be harmful to their health.”
Eli Lilly, which is developing retatrutide, says on its counterfeit and safety page that the drug is in Phase 3 trials and “has not been approved by the U.S. Food and Drug Administration (‘FDA’) or any other regulator in the world.” It describes sellers offering it “without requiring a prescription under the pretext that it is ‘research use only.'” The retatrutide guide explains why trial results do not transfer to these vials.
📨 Get Free Peptide Risk Guides Alerts
Free · No spam · Unsubscribe anytime
Research use only peptides: what the label tells you about the vial
Medicines are made under current good manufacturing practice rules. For example, every batch of a drug product that is meant to be sterile or pyrogen-free must undergo appropriate laboratory testing to show it meets those requirements. A seller who insists its product is not for human use is, by its own description, not claiming to meet the standards that apply to human drugs.
| What a medicine comes with | What a research use only vial typically lacks |
|---|---|
| FDA review of safety and effectiveness for a stated use | No review. The seller disclaims any human use |
| Batch testing for sterility and endotoxins when the product is injectable | No legal requirement the seller says it meets. Any test report is supplied by the seller |
| A label with strength, ingredients, lot number and expiry that the manufacturer must stand behind | A label written so the seller can deny that anyone was meant to inject it |
| Prescribing information listing known risks and interactions | No risk information. For many of these peptides the FDA says little or no human safety data exist |
| A traceable supply chain and adverse-event reporting duties | Unknown origin. Often a powder that must be mixed by the buyer |
On that last risk row, the FDA’s compounding safety-risk page is blunt. For TB-500 it says the FDA “has not identified any human exposure data.” For KPV it says it has not identified human exposure data for any route. For BPC-157 it says it has identified “no, or only limited, safety-related information” for the proposed routes. More detail is in the BPC-157 and TB-500 guides.
What testing of these products has found
Independent analyses are small, but they show what can happen when no one is accountable for quality.
- Semaglutide vials, 2024. Researchers in Hungary made test purchases of semaglutide sold online without a prescription (Ashraf et al., J Med Internet Res, 2024). Three vials arrived; three ordered Ozempic pens never did. The authors say some sellers in this market describe their unbranded “laboratory products” as for research only. In the three vials, measured semaglutide purity was 7.7% to 14.37%, against the 99% claimed on the labels. The semaglutide content was 28.56% to 38.69% higher than labeled, and bacterial endotoxin was detected in all three. No living microorganisms were found at the time of testing.
- Unexpected molecules, 2018. A German doping-control laboratory analyzing black-market growth products identified glycine-extended versions of GHRP-6, GHRP-2 and ipamorelin, plus a growth hormone carrying one extra amino acid (Krug et al., Growth Horm IGF Res, 2018). These are variants no one has tested in people.
- Seized “nootropic” peptides, 2020. Scientists at Belgium’s public health institute found Selank and Semax in two suspicious preparations seized in 2017 and 2018 (Vanhee et al., Drug Test Anal, 2020). The authors noted these peptides were openly sold online as powders for injection or as nasal sprays, and to their knowledge had not completed any clinical trials.
None of these studies tested a large number of products, so they cannot say how common each problem is. They do show that the label on the vial is not a reliable guide to what is inside. A certificate of analysis does not settle the question either; the COA guide explains why.
Why sellers use the label
The label lets a seller avoid stating any human use on the vial itself. As the regulations above show, that defense depends on the seller’s other claims, advertising and conduct, which is why the FDA has issued warning letters despite the disclaimers. For a buyer, the practical point is different. The label is the seller telling you in writing that it does not stand behind the product’s safety in people.
Signs a “research” product is being sold as a drug
- Health or body claims on the website or social media: fat loss, healing, anti-aging, libido, recovery.
- Dosing charts, “protocols,” calculators or mixing instructions supplied with a “not for human use” product.
- Sterile water, syringes or alcohol swabs sold as a bundle with the vial.
- Names of approved drugs, or codes standing in for trial drugs, used to signal what the vial is “really” for.
- Customer reviews describing personal use, left up by the seller.
The FDA’s research use only warnings do not mean every vial is contaminated. They mean no one has taken legal responsibility for whether it is. Injection adds its own risks, covered in the injection infection guide.
If you have had a reaction to a research use only product, a doctor or pharmacist can help, and bringing the vial and any packaging makes that easier. You can report the product and its seller to the FDA through MedWatch, whatever the label claims it was for.
Sources
- eCFR: 21 CFR 809.10, labeling for in vitro diagnostic products
- eCFR: 21 CFR 312.6, labeling of an investigational new drug
- US Code (govinfo): 21 U.S.C. 321, definitions (“drug”)
- eCFR: 21 CFR 201.128, meaning of “intended uses”
- eCFR: 21 CFR 211.167, special testing requirements
- FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
- Eli Lilly and Company: Protect yourself from counterfeit and unsafe, mass compounded products
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024.
- Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018.
- Vanhee C, et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal. 2020.
- FDA: MedWatch adverse event reporting